TGFB1 and cardiac hypertrophy: Previous reports showed that AST-IV could attenuate myocardial fibrosis by inhibiting TGF-β1 signalling, mediate protection against cardiac hypertrophy via inhibiting the Ca2+/CaN signalling, and reduce cardiac ischaemia/reperfusion injury via energy regulation 27,37,38.